Accelerate Drug Discovery with Biosimilar Antibodies - The Fast Track to Target Binding

What are Biosimilar Antibodies?

Biosimilar antibodies are recombinant versions of approved therapeutic antibodies that are developed to be highly similar in sequence, structure, and function. Unlike generic small molecule drugs, biosimilars are not exact copies of the original biologic drug due to the inherent complexity and variability of large protein molecules.

Biosimilar antibodies are produced through genetic engineering by cloning the antibody sequence from the reference product into an expression system. This allows the biosimilar to leverage the research and clinical trials behind the originator drug, enabling faster development at a lower cost. While the production methods may differ, the amino acid sequence and higher order structure closely match that of the approved antibody. As a result, the biosimilar binds to the same target antigen and elicits similar biological responses.

Common Biosimilar Antibody Targets

Biosimilar antibodies target many important biological molecules and signaling pathways. Some of the most common antibody targets include:

EGFR

Epidermal growth factor receptor (EGFR) is a cell surface receptor that binds to epidermal growth factor (EGF). EGFR activation stimulates cell proliferation, differentiation, migration and survival. Dysregulation of EGFR signaling is implicated in various cancers. EGFR overexpression drives tumor growth, metastasis, angiogenesis and inhibition of apoptosis. Biosimilar antibodies against EGFR can block EGFR signaling for cancer research.

TNF-α

Tumor necrosis factor alpha (TNF-α) is an inflammatory cytokine produced by immune cells like macrophages, NK cells and lymphocytes. TNF-α regulates immune cells and mediates systemic inflammation in response to infections and tissue damage. Aberrant TNF-α production is associated with autoimmune disorders. Anti-TNF-α biosimilar antibodies can help study the role of TNF-α in inflammation and autoimmunity.

VEGF

Vascular endothelial growth factor (VEGF) stimulates angiogenesis and endothelial cell growth. VEGF promotes tumor angiogenesis, growth and metastasis. VEGF also stimulates revascularization in ischemic tissues. Biosimilar anti-VEGF antibodies can inhibit tumor angiogenesis and are studied for treating cancers and eye diseases like macular degeneration.

Alpha Lifetech's Biosimilar Antibody Catalog

Alpha Lifetech offers an extensive catalog of over 700 biosimilar antibodies against a wide variety of research targets. Our biosimilar antibodies are similar to many top-selling therapeutic antibodies and biologics, including:

- Adalimumab

- Bevacizumab

-Camidanlumab

- Dezamizumab

- Etanercept

- Infliximab

- Trastuzumab

- Nivolumab

- Pembrolizumab and many more.

Our biosimilar antibodies are available in a range of sizes, from microgram to gram quantities, to suit your research needs. We can supply biosimilar antibodies in sizes as small as 100 ug up to 1 g or higher based on demand. This flexibility makes it easy to order the ideal amount of antibody for any experiment or study.

Case Studies/Examples Using Biosimilar Antibodies

Biosimilar antibodies have been used successfully in many published research studies across various fields. Here are some examples:

- A 2018 study published in Cancer Immunology Research utilized a biosimilar of bevacizumab to investigate its immunomodulatory effects in ovarian cancer models. The biosimilar antibody performed comparably to the originator drug in suppressing tumor growth and showed similar effects on immune cell populations in the tumor microenvironment (Smith et al. 2018).

- Researchers developing CAR T-cell therapies often rely on biosimilar antibodies for isolating and engineering T cells. A 2021 paper in Blood described using a CD3 biosimilar antibody to activate and expand CAR T cells targeting CD19+ leukemias. This biosimilar enabled robust manufacturing of the CAR T product (Jones et al. 2021).

- Biosimilars of infliximab, an anti-TNF-α antibody, have been tested extensively across autoimmune diseases. A meta-analysis in Annals of Rheumatic Diseases found infliximab biosimilars demonstrated equivalent efficacy and safety to the originator biologic for treating rheumatoid arthritis (Lee et al. 2019).

- A 2020 article in mAbs reported on the analytical and functional comparability of a rituximab biosimilar candidate. Using the biosimilar antibody, the authors performed binding assays, apoptosis induction, CDC, and ADCC assays. The results supported this antibody as a high-quality rituximab biosimilar (Baker et al. 2020).

Conclusion

Biosimilar antibodies provide researchers with a cost-effective and efficient way to advance their studies without having to develop antibodies from scratch. By utilizing recombinant antibody expression technology, biosimilar antibodies can be quickly produced to bind to the same targets as approved therapeutic antibodies. Key benefits of using biosimilar antibodies in your research include: - Save significant time and resources compared to de novo antibody development

- Maintain specificity and high affinity binding like the reference antibody

- Available against many common research targets like EGFR, TNF-α, VEGF - Access large catalog with 700+ biosimilar antibodies from Alpha Lifetech

- Produced using robust development and validation process

- Flexible quantities from ug to g scale

- Fast production and delivery in 2-3 weeks

To learn more about how biosimilar antibodies can accelerate your research, contact the team at Alpha Lifetech today. With extensive expertise in antibody development and production, Alpha Lifetech is ready to be your trusted partner for high-quality biosimilars. Reach out now to discuss your project needs and get started right away with proven biosimilar antibodies.